Prospective trial comparing sugammadex vs neostigmine reversal of neuromuscular block after thoracic anesthesia
- Conditions
- euromuscular block is commonly adopted during general anesthesia to facilitate tracheal intubation, mechanical ventilation and surgical manipulation. At the end of anesthesia it very important to avoid residual neuromuscular block to ensure adequate respiratory function preventing postoperative pulmonary complications. This trial compares the neuromuscular block reversal with different drugs (sugammadex vs neostigmine) after thoracic anesthesia.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- EUCTR2014-002021-35-IT
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 266
- Subjects scheduled for pulmonary resection, lebectomy, pneumonectomy, bullectomy, pleurodesis
- Age 18-70 years
- ASA class 1,2,3
- Body Mass Index (BMI) 18-30 kg/m2
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 66
- Subject scheduled for esofagectomy, thoracectomy, vascular resection
- COPD Gold class III and IV, respiratory infection, asthma
- Preoperative FEV1 < 60% of predicted, FEV1/FVC<70%
- Preoperative DLCO2/VA<60% of predicted
- Preoperative SpO2<92%, PaO2/FiO2<300
- Cardiovascular desease with a METS score less than 4
- Neuromuscular disorder
- Kidney insufficiency (eGFR<30 ml/min/1,73m2)
- Pregnant women
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method